Arcus Biosciences Inc (RCUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has a cash flow conversion efficiency ratio of -0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-138.00 Million) by net assets ($524.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Arcus Biosciences Inc (RCUS) balance sheet quality index to measure how much of total assets are equity-financed.
Arcus Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arcus Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RCUS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Arcus Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcus Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kinik Co
TW:1560
|
0.056x |
|
WYNN MACAU LTD ADR/10
F:8WY0
|
N/A |
|
Quilter PLC
JSE:QLT
|
0.318x |
|
Becle S.A.B. de C.V
MX:CUERVO
|
0.034x |
|
Almonty Industries Inc
TO:AII
|
0.026x |
|
Salzgitter AG
XETRA:SZG
|
0.015x |
|
Bombardier Inc
TO:BBD-A
|
-1.613x |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Arcus Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arcus Biosciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see RCUS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $631.00 Million | $-482.00 Million | -0.764x | -117.93% |
| 2024-12-31 | $485.00 Million | $-170.00 Million | -0.351x | +47.08% |
| 2023-12-31 | $462.00 Million | $-306.00 Million | -0.662x | -199.35% |
| 2022-12-31 | $657.00 Million | $438.00 Million | 0.667x | +318.98% |
| 2021-12-31 | $841.45 Million | $-256.17 Million | -0.304x | -237.56% |
| 2020-12-31 | $502.30 Million | $111.17 Million | 0.221x | +149.36% |
| 2019-12-31 | $163.84 Million | $-73.46 Million | -0.448x | -145.00% |
| 2018-12-31 | $234.94 Million | $-43.00 Million | -0.183x | -12.37% |
| 2017-12-31 | $153.87 Million | $-25.06 Million | -0.163x | -25.14% |
| 2016-12-31 | $99.46 Million | $-12.94 Million | -0.130x | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more